The US Hypophosphatasia drugs market size is projected to reach USD xx billion by 2028 from USD xx billion in 2019, exhibiting a CAGR of xx% during the forecast period.
Hypophosphatasia (HPP) is a rare genetic disorder characterized by the abnormal development of bones and teeth. Treatment and management of hypophosphatasia (HPP) is symptomatic and supportive, it aims at addressing symptoms of disease such as thiazide diuretics for hypercalcemia, ventilator support, occupational therapy, and surgery for bone fractures. The HPP community are helping to bring programs that will bring new and treatment options to people with rare diseases. Currently, clinical trials are conducted, wherein many organizations are actively participating in several research programs to develop novel therapies for infantile and juvenile onset hypophosphatasia treatment. Introduction of several novel therapies, breakthrough therapy designation, orphan drug designation for rare diseases, financial incentives and grants by the government, clinical studies on safety and efficacy of products, is expected to be the biggest infantile and juvenile onset hypophosphatasia treatment over the forecast period.
Increasing number of patients with hypophosphatasia, family history of hypophosphatasia, strong product pipeline, and increasing financial support to researchers for developing new innovative drugs for treatment of hypophosphatasia are likely to drive the hypophosphatasia market during the forecast period. In addition, increase in special designation from the regulatory authorities to offer a treatment to the patients as quickly as possible is enhancing the market.